Home -- Technology
Technology

We import from New Zealand and Australia, and now we are the authorised distributor of Proliant.

In China, we have long-term cooperation with Jiangsu University of Technology. Many doctors, who are listed below are our technical consultants.


1. Dr. Chang Shan

Associate Professor, Director, from Jiangsu University of Technology, Institute of Bioinformatics and Medical Engineering

Since 2004, Dr. Chang Shan has been working on protein-ligand interactions and complex structure prediction, protein folding methods, and computer-aided drug design. She has participated in the Biomacromolecular Interaction Prediction Competition (CAPRI) initiated by the European Molecular Biology Laboratory and the European Bioinformatics Institute, and has achieved good results. In September 2012, a one-year postdoctoral study was conducted at the University of Missouri-Columbia, focusing on the design of protein-RNA molecular docking scoring functions.


2. Dr. Kong Ren

From Jiangsu University of Technology, Institute of Bioinformatics and Medical Engineering

Dr. Kong Ren has been engaged in molecular modeling and drug design methodology and applied research for 12 years. His main research includes protein ligand binding mode and binding free energy prediction; virtual screening of drug molecules based on protein structure and kinetic properties; analysis of drug molecular structure activity relationship and so on. After graduating from the Ph.D., he worked in the New Drug Research and Development Company for three years. As a core member, he participated in the research and development of new anti-tumor drugs and obtained international invention patents. In 2011, he entered the Institute of Werrith Hospital of Cornell University, and engaged in postdoctoral research. He used system biology and chemical informatics to conduct rapid drug screening and drug relocation design for tumor and nervous system diseases, and he made research on individualized treatment methods for cancer. He has published more than ten papers in journals such as Clinical Cancer Research, Journal of Structural Biology, European Journal of Medicinal Chemistry, BBA–Proteins and Proteomics, Medicinal Chemistry, and Molecular Simulation. And he has applied for a number of invention patents in major markets such as China, the United States, Japan, and Europe.

 

3. Dr. Piao Lianhua

From Jiangsu University of Technology, Institute of Bioinformatics and Medical Engineering

Dr. Piao Lianhua has been engaged in molecular biology and related experimental research of tumor cells for 8 years. Her main research includes screening new and effective molecular targets for molecular targeted therapy, and studying its molecular mechanisms and pathways related to cancer occurrence and development. After graduating from the Ph.D. of Tokyo University, she made research at Anderson Cancer Center and Chicago University in the USA, focusing on histone methyltransferases and histone demethylases related to tumorigenesis and development, looking for new non-histone proteins substrate and studying the mechanism of action of non-histone lysine residue methylation in tumorigenesis and progression. He has published more than ten research papers in well-known magazines such as Nature Communication, Cell Report and Neoplasia.

 

4. Dr. Xu Lei

From Jiangsu University of Technology, Institute of Bioinformatics and Medical Engineering

Dr. Xu Lei has been engaged in computer aided molecular design methodology and applied research for a long time. In January 2014, he joined School of Pharmacy of Zhejiang University to study the application of drug design theory and methods in important targets such as MIF, GPCR, ion channel and AR, and analyze the molecular mechanism of protein-protein interactions and drug resistance mutations. He has published 13 SCI papers in scientific journals such as Advanced Drug Delivery Reviews, Journal of Medicinal Chemistry, Drug Discovery Today, Scientific Reports, Journal of Chemical Information and Modeling, Journal of Cheminformatics,Physical Chemistry Chemical Physics, Journal of Physical Chemistry B, Molecular Biosystems, for which the impact factor is all greater than 3, and the average impact factor is 4.87.

 

5. Dr. Zhang Dawei

From Jiangsu University of Technology, Institute of Bioinformatics and Medical Engineering

Dr. Zhang Dawei has been engaged in drug screening methodology and applied research for 7 years. His research includes the establishment and application of protein-protein interactions, protein-DNA interactions and screening methods for protein allosteric inhibitors. During the Ph.D., he hosted an innovation fund of Beijing Union Medical College and participated in 2 national natural science funds. He has published more than 20 academic papers in domestic and foreign journals such as Analytical Biochemistry and Pharmaceutical Journal, of which 8 articles were searched by SCI.

 

6. Dr. Liu Mengmeng

From Jiangsu University of Technology, Institute of Bioinformatics and Medical Engineering

Dr. Liu Mengmeng is engaged in molecular biology research of medicinal fungi. Her research includes R&D on fungal interaction mechanism and molecular phylogenetic study of precious medicinal fungi. He has published 18 academic papers in domestic and foreign journals such as Scientific Report and Pharmaceutical Journal, of which 11 articles were searched by SCI.

 



Mobile station
CopyRight © 2018-2019 Jiangsu EMMASH Biological Technology Co., Ltd. All rights reserved. Sitemap   Designed by Zhonghuan Internet